We are live on ! Find out more
CC

Casdin Capital Portfolio holdings

AUM $1.32B
1-Year Est. Return 76.62%
This Fund
S&P 500
This Quarter Est. Return
+9.75%
1 Year Est. Return
+76.62%
3 Year Est. Return
+218.92%
5 Year Est. Return
+86.82%
10 Year Est. Return
+4,823.46%
AUM
$3.94B
AUM Growth
+$582M
Cap. Flow
+$429M
Cap. Flow %
10.9%
Top 10 Hldgs %
57.23%
Holding
59
New
11
Increased
8
Reduced
3
Closed
5

Top Buys

Rank Stock Value
1
VERV
Verve Therapeutics
VERV
+$126M
2
IPSC icon
Century Therapeutics
IPSC
+$81.4M
3
OMIC
Singular Genomics Systems, Inc. Common Stock
OMIC
+$69.6M
4
AMRS
Amyris Inc.
AMRS
+$44.7M
5
ME
23andMe Holding Co
ME
+$28.5M

Top Sells

Rank Stock Value
1
BNR
Burning Rock Biotech
BNR
+$22.8M
2
ADVM
Adverum Biotechnologies
ADVM
+$21.8M
3
TSHA icon
Taysha Gene Therapies
TSHA
+$16.7M
4
CNST
Constellation Pharmaceuticals, Inc.
CNST
+$11.7M
5
DYN icon
Dyne Therapeutics
DYN
+$9.47M

Sector Composition

Rank Sector Weight
1 Healthcare 88.3%
2 Materials 1.25%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NVTA
1
DELISTED
Invitae Corporation
NVTA
$412M 10.45%
12,203,669
– –
BLFS icon
2
BioLife Solutions
BLFS
$1.55B
$331M 8.41%
7,440,107
– –
FATE icon
3
Fate Therapeutics
FATE
$291M
$295M 7.49%
3,400,000
– –
EXAS
4
DELISTED
Exact Sciences
EXAS
$293M 7.45%
2,360,186
– –
VERV
5
DELISTED
Verve Therapeutics
VERV
$183M 4.65%
+3,038,167
New +$126M
PACB icon
6
Pacific Biosciences
PACB
$450M
$175M 4.44%
5,000,000
– –
ALNY icon
7
Alnylam Pharmaceuticals
ALNY
$28.9B
$170M 4.3%
1,000,000
+120,000
+14% +$17.6M
BPMC
8
DELISTED
Blueprint Medicines
BPMC
$136M 3.46%
1,550,000
– –
TWST icon
9
Twist Bioscience
TWST
$6.14B
$133M 3.38%
1,000,000
– –
DNLI icon
10
Denali Therapeutics
DNLI
$3.66B
$126M 3.21%
1,610,000
– –
RLAY icon
11
Relay Therapeutics
RLAY
$4.05B
$123M 3.13%
3,375,058
– –
AGIO icon
12
Agios Pharmaceuticals
AGIO
$1.82B
$119M 3.03%
2,165,000
– –
CDNA icon
13
CareDx
CDNA
$2.55B
$109M 2.77%
1,193,335
– –
BEAM icon
14
Beam Therapeutics
BEAM
$2.67B
$105M 2.68%
818,820
– –
CDXS icon
15
Codexis
CDXS
$159M
$98.1M 2.49%
4,330,000
– –
IPSC icon
16
Century Therapeutics
IPSC
$357M
$94.1M 2.39%
+3,206,380
New +$81.4M
OMIC
17
DELISTED
Singular Genomics Systems, Inc. Common Stock
OMIC
$74M 1.88%
+89,762
New +$69.6M
RVMD icon
18
Revolution Medicines
RVMD
$39.2B
$73.2M 1.86%
2,305,000
+460,465
+25% +$16.1M
DMTK
19
DELISTED
DermTech, Inc. Common Stock
DMTK
$72.5M 1.84%
1,745,000
– –
SRPT icon
20
Sarepta Therapeutics
SRPT
$1.62B
$68.8M 1.75%
885,000
+335,000
+61% +$25.4M
ADPT icon
21
Adaptive Biotechnologies
ADPT
$3.72B
$58.8M 1.49%
1,440,000
+290,000
+25% +$11.3M
ONC
22
BeOne Medicines Ltd
ONC
$32.4B
$51.5M 1.31%
150,000
– –
AMRS
23
DELISTED
Amyris Inc.
AMRS
$49.1M 1.25%
+3,000,000
New +$44.7M
GBT
24
DELISTED
Global Blood Therapeutics, Inc.
GBT
$45.9M 1.16%
1,310,000
+410,000
+46% +$16M
CNST
25
DELISTED
Constellation Pharmaceuticals, Inc.
CNST
$45.3M 1.15%
1,341,000
-459,000
-26% -$11.7M
1
2 3

Similar funds

MDSL
M.D. Sass LLC New York $1.32B AUM 16.01% 1-Year Est. Return
CP
Cumberland Partners Toronto, Ontario, Canada $1.32B AUM 27.83% 1-Year Est. Return
HCM
Hilton Capital Management Garden City, New York $1.32B AUM 15.59% 1-Year Est. Return
MIM
Marco Investment Management Atlanta, Georgia $1.33B AUM 32.43% 1-Year Est. Return
MRL
Mantle Ridge LP New York $1.33B AUM 11.36% 1-Year Est. Return
SWM
SHP Wealth Management Plymouth, Massachusetts $1.33B AUM
MCM
Mill Capital Management Concord, North Carolina $1.31B AUM 17.4% 1-Year Est. Return
B
BloombergSen Toronto, Ontario, Canada $1.31B AUM 8.32% 1-Year Est. Return

Casdin Capital's Q2 2021 Portfolio in Review

As of Q2 2021, Casdin Capital held 59 positions worth $3.94B, up 17% from $3.36B the previous quarter. Its ten largest holdings account for 57% of the portfolio.

Casdin Capital deployed $429M of net new capital in Q2 2021, opening 11 new positions and adding to 8 existing holdings. Its largest new stake was Verve Therapeutics: 3,038,167 shares worth $183M.

By sector, the portfolio is most concentrated in Healthcare at 88% of assets, up from 86% a quarter earlier, followed by Materials.

On the sell side, the largest reduction was Constellation Pharmaceuticals, Inc., an estimated $11.7M trimmed.

  • Casdin Capital's largest Q2 2021 buy was Verve Therapeutics: 3,038,167 shares worth $183M.
  • Casdin Capital added most to Sarepta Therapeutics in Q2 2021, an estimated $25.4M increase.
  • Casdin Capital's biggest Q2 2021 reduction was Constellation Pharmaceuticals, Inc., cutting an estimated $11.7M.
  • Casdin Capital fully exited Burning Rock Biotech in Q2 2021, selling an estimated $22.8M.
  • Casdin Capital's ten largest holdings make up 57% of its $3.94B portfolio in Q2 2021.
  • Casdin Capital opened 11 new positions and closed 5 in Q2 2021.
  • Casdin Capital's portfolio value rose 17% quarter-over-quarter to $3.94B.

Based on Casdin Capital's 13F filing for Q2 2021, filed 16 Aug 2021.